# Practical Feasibility Assessment: Astrocyte Reactivity Therapeutic Hypotheses
## Most Viable Hypotheses for Drug Development
Based on the critique, I'll focus on the three most promising hypotheses from a pharmaceutical development perspective:
---
## **HYPOTHESIS 3: TET2 Activation (Revised Confidence: 0.50)**
### **Druggability Assessment: MODERATE**
- **Target Class**: Epigenetic enzyme (α-ketoglutarate-dependent dioxygenase)
- **Structural Information**: Crystal structures available (PDB: 4NM6, 6PUO)
- **Active Site**: Well-characterized catalytic domain with cofactor binding sites
- **Challenges**: Large protein (2002 AA), multiple domains, requires α-ketoglutarate and Fe2+ cofactors
### **Existing Chemical Matter**
**Direct TET2 Activators:**
- **Bobcat339** - Small molecule TET2 activator (Constellation Pharmaceuticals, discontinued 2021)
- **SKLB-677** - TET2 stabilizer, preclinical (Sichuan University)
- **Vitamin C (Ascorbic Acid)** - Indirect activator via cofactor recycling, clinical use
**Indirect Approaches:**
- **IDH1/2 inhibitors**: Ivosidenib (Tibsovo®), Enasidenib (Idhifa®) - restore TET2 activity by reducing 2-HG
- **DNMT inhibitors**: 5-azacytidine (Vidaza®), decitabine - synergistic with TET2
### **Competitive Landscape**
- **Constellation Pharmaceuticals** (acquired by MorphoSys 2021): Discontinued TET programs
- **Epizyme** (acquired by Ipsen 2022): Focus on EZH2, limited TET activity
- **Academic leaders**: Yi Zhang (Harvard), Anjana Rao (La Jolla Institute)
- **No active CNS-focused TET2 programs identified**
### **Safety Concerns**
- **Genome-wide demethylation**: Risk of oncogene activation
- **Hematologic toxicity**: TET2 mutations associated with clonal hematopoiesis
- **Developmental effects**: Critical role in embryogenesis
- **BBB penetration**: Most epigenetic drugs have poor CNS exposure
### **Development Timeline & Costs**
- **Lead Optimization**: 2-3 years, $15-25M (BBB penetration major challenge)
- **IND-enabling**: 1-2 years, $10-15M
- **Phase I/IIa**: 3-4 years, $25-40M
- **Total to PoC**: 6-9 years, $50-80M
---
## **HYPOTHESIS 5: P2Y1/P2X7 Modulation (Revised Confidence: 0.55)**
### **Druggability Assessment: HIGH**
- **Target Class**: G-protein coupled receptor (P2Y1) + Ligand-gated ion channel (P2X7)
- **Precedent**: Multiple marketed drugs targeting purinergic receptors
- **Structural**: P2Y1 crystal structure (PDB: 4XNV), P2X7 cryo-EM (PDB: 6U9W)
### **Existing Chemical Matter**
**P2Y1 Agonists:**
- **MRS2365** - Potent selective agonist, research tool
- **2-MeSADP** - Clinical-stage platelet aggregation inhibitor
- **ARC69931MX** - Selective agonist, preclinical
**P2X7 Antagonists:**
- **JNJ-47965567** (Janssen) - Phase II completed for mood disorders (NCT02902601)
- **GSK1482160** (GSK) - Phase I completed, discontinued
- **A-740003** (Abbott) - Preclinical, high CNS penetration
- **CE-224,535** (Pfizer) - Development discontinued
### **Competitive Landscape**
- **Janssen**: Most advanced with JNJ-47965567, but mood disorders focus
- **Roche/Hoffmann-La Roche**: P2X7 programs for neuroinflammation
- **Evotec**: P2X7 platform, partnered with Bristol Myers Squibb
- **RedoxTherapies**: P2Y1 programs for neuroprotection
### **Combination Strategy Precedent**
- **Dual mechanism approaches**: Common in CNS (e.g., olanzapine/fluoxetine)
- **Purinergic polypharmacology**: Established concept
### **Safety Concerns**
**P2Y1 Agonists:**
- **Bleeding risk**: Platelet aggregation effects
- **Hypotension**: Vasodilation effects
- **GI effects**: Smooth muscle activation
**P2X7 Antagonists:**
- **Immune suppression**: Reduced inflammasome activation
- **Infection risk**: Impaired pathogen clearance
- **Generally well-tolerated** in completed trials
### **Development Timeline & Costs**
- **Lead Optimization**: 1-2 years, $10-15M (leverage existing compounds)
- **Combination formulation**: 1 year, $5-8M
- **IND-enabling**: 1-1.5 years, $8-12M
- **Phase I/IIa**: 2-3 years, $20-35M
- **Total to PoC**: 5-7 years, $43-70M
---
## **HYPOTHESIS 1: HK2 Metabolic Targeting (Revised Confidence: 0.45)**
### **Druggability Assessment: MODERATE-LOW**
- **Target Class**: Metabolic enzyme (hexokinase)
- **Challenges**: Glucose metabolism enzyme - systemic effects likely
- **Isoform selectivity**: Need to avoid HK1 (brain-specific) inhibition
### **Existing Chemical Matter**
**HK2 Activators (Limited):**
- **No direct small molecule activators reported**
- **Glucose/mannose analogs**: 2-deoxyglucose (paradoxically inhibitory)
- **Metabolic enhancers**: Dichloroacetate (indirect via PDK inhibition)
**HK Inhibitors (for comparison):**
- **2-Deoxyglucose** - Clinical trials for cancer (NCT00096707)
- **3-Bromopyruvate** - Research tool, highly toxic
- **Lonidamine** - Marketed in Europe for cancer
### **Major Development Challenges**
1. **No validated HK2 activators exist**
2. **Systemic glucose metabolism effects**
3. **Diabetes/hypoglycemia risk**
4. **Limited chemical starting points**
### **Competitive Landscape**
- **No active HK2 activator programs identified**
- **Cancer metabolism focus**: HK2 inhibition approaches only
- **Academic interest**: Limited translational efforts
### **Safety Concerns**
- **Hypoglycemia**: Major dose-limiting toxicity
- **Metabolic acidosis**: Lactate accumulation
- **Cardiac effects**: HK2 critical for cardiac metabolism
- **Diabetic complications**: Glucose homeostasis disruption
### **Development Assessment: NOT RECOMMENDED**
- **High risk/low probability**: No chemical starting point
- **Significant safety concerns**: Systemic glucose effects
- **Better alternatives exist**: Target downstream pathways instead
---
## **OVERALL RECOMMENDATIONS**
### **Priority 1: P2Y1/P2X7 Combination Approach**
- **Rationale**: Established druggable targets, existing compounds, manageable safety profile
- **Next Steps**:
1. License JNJ-47965567 (P2X7 antagonist)
2. Develop brain-penetrant P2Y1 agonist
3. Establish combination pharmacology
- **Estimated Investment**: $43-70M to Phase IIa PoC
### **Priority 2: TET2 Activation (Long-term)**
- **Rationale**: Novel mechanism, high unmet need, but significant development challenges
- **Next Steps**:
1. Develop BBB-penetrant TET2 activators
2. Establish CNS-selective dosing strategy
3. Comprehensive safety assessment
- **Estimated Investment**: $50-80M to Phase IIa PoC
### **Not Recommended: HK2 Metabolic Targeting**
- **Rationale**: Insufficient chemical matter, high safety risk, limited competitive advantage
### **Alternative Approaches to Consider**
1. **Repurposing Strategy**: Screen approved CNS drugs for astrocyte phenotype modulation
2. **Biomarker Development**: Develop A1/A2 diagnostic assays for patient stratification
3. **Academic Partnerships**: Collaborate with leaders in astrocyte biology for target validation
**Bottom Line**: The purinergic combination approach offers the best near-term opportunity with manageable risk and established precedent. TET2 represents a higher-risk, higher-reward longer-term opportunity requiring significant innovation in drug delivery and selectivity.